Navigation Links
Wayne State part of team for license on new ways to manage cancer with green tea extracts
Date:11/26/2013

DETROIT Wayne State University, along with McGill University and the Hong Kong Polytechnic University, have executed an exclusive worldwide license with Viteava Pharmaceutical Inc. for an intellectual property portfolio claiming composition of matter and/or methods of use of novel analogs and derivatives of the green tea flavonoid, (-)epigallocatechin-3-gallate (EGCG).

This intellectual property resulted from a long-standing collaboration between Q. Ping Dou, Ph.D., professor of oncology, pharmacology and pathology at Wayne State University's School of Medicine and the Karmanos Cancer Institute and Tak-Hang Chan, Ph.D., professor emeritus of chemistry at McGill University and the Hong Kong Polytechnic University. The intellectual property portfolio is owned by Wayne State University, McGill University, the University of South Florida, the Moffitt Cancer Center and the Hong Kong Polytechnic University. Patents have been issued in the U.S., Japan and China and are pending in other international jurisdictions.

Viteava Pharmaceuticals will focus on the development of novel approaches to manage cancer and related conditions. It has identified VPE001, a prodrug of EGCG with improved bioavailability and potency, as its lead drug candidate expected to enter clinical development in 2015. Initial clinical indications may include the treatment of uterine fibroids and/or delaying the progression of cancer in high-risk, early-stage chronic lymphocytic leukemia patients.

"My laboratory was the first to identify inhibition of proteasomal chymotrypsin-like activity as an important mechanism of action of EGCG," said Dou. "We also know that EGCG can affect, albeit to a lesser extent, other important pathways, such as PI3K/Akt/mTOR signaling. Viteava's drug candidates target diseases where these pathways are dysregulated."

"I am very excited to work together with Viteava Pharmaceuticals to move towards the clinic drug candidates designed through a deep understanding of structure-activity relationships involving the EGCG pharmacophore that my laboratory has researched for many years," said Chan. "We have been working diligently to translate the well-established health benefits of green tea and its major active ingredient, EGCG, to design commercially-viable drug candidates."

Viteava Pharmaceuticals is a privately-held start-up drug development company established to commercialize this intellectual property portfolio. The company's strategy focuses principally on clinical indications where green tea extracts have been demonstrated to elicit biological responses in human studies. Viteava's drug candidates are designed to improve these treatment regimens and achieve better clinical outcomes, while retaining a high level of safety. By regulating multiple pathways important to the progression of diseases such as cancer, Viteava's drug candidates are expected to provide advantages over more potent and more selective drugs that usually only elicit temporary responses together with a high level of toxicity.

Pou's research stemmed from a grant and administrative supplement of over $1.6 million from the National Cancer Institute of the National Institutes of Health (grant number 1R01CA120009). The grant, "Roles of polymorphic COMT, tea polyphenols and proteasome in cancer prevention," was initially funded in 2006.


'/>"/>

Contact: Julie O'Connor
julie.oconnor@wayne.edu
313-577-8845
Wayne State University - Office of the Vice President for Research
Source:Eurekalert  

Related medicine news :

1. Wayne State University researcher examines proteins role in diabetic retinopathy
2. Wayne State University researcher seeks to understand link between obesity, flu severity
3. Algae extract increases good cholesterol levels, Wayne State research finds
4. Wayne State develops better understanding of memory retrieval between children and adults
5. Wayne State research team finds possible clue to progression of MS
6. Wayne State researchers say adolescent smoking prevention programs still critical
7. Wayne State University researcher recognized by American Psychological Association
8. CDC funds Wayne State University research to understand, prevent teen dating violence
9. Wayne State researcher finds possible clue to childrens early antisocial behavior
10. Wayne State University researcher to evaluate success of text message diabetes intervention
11. Wayne State embarks on study to improve identification of women at high risk of stroke
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Wayne State part of team for license on new ways to manage cancer with green tea extracts
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology: